These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

613 related articles for article (PubMed ID: 15140544)

  • 1. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
    Ryu JS; Hong YC; Han HS; Lee JE; Kim S; Park YM; Kim YC; Hwang TS
    Lung Cancer; 2004 Jun; 44(3):311-6. PubMed ID: 15140544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
    Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Zhou W; Gurubhagavatula S; Liu G; Park S; Neuberg DS; Wain JC; Lynch TJ; Su L; Christiani DC
    Clin Cancer Res; 2004 Aug; 10(15):4939-43. PubMed ID: 15297394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.
    Gurubhagavatula S; Liu G; Park S; Zhou W; Su L; Wain JC; Lynch TJ; Neuberg DS; Christiani DC
    J Clin Oncol; 2004 Jul; 22(13):2594-601. PubMed ID: 15173214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
    Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Sun Y; Xu BH; Lin DX
    Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):972-5. PubMed ID: 16061005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.
    Giachino DF; Ghio P; Regazzoni S; Mandrile G; Novello S; Selvaggi G; Gregori D; DeMarchi M; Scagliotti GV
    Clin Cancer Res; 2007 May; 13(10):2876-81. PubMed ID: 17504986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of the DNA repair gene XPD Asp312Asn polymorphism with p53 gene mutations in tobacco-related non-small cell lung cancer.
    Gao WM; Romkes M; Day RD; Siegfried JM; Luketich JD; Mady HH; Melhem MF; Keohavong P
    Carcinogenesis; 2003 Oct; 24(10):1671-6. PubMed ID: 12844488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
    Quintela-Fandino M; Hitt R; Medina PP; Gamarra S; Manso L; Cortes-Funes H; Sanchez-Cespedes M
    J Clin Oncol; 2006 Sep; 24(26):4333-9. PubMed ID: 16896002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Zhou C; Ren S; Zhou S; Zhang L; Su C; Zhang Z; Deng Q; Zhang J
    Jpn J Clin Oncol; 2010 Oct; 40(10):954-60. PubMed ID: 20462983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.
    Liu D; O'Day SJ; Yang D; Boasberg P; Milford R; Kristedja T; Groshen S; Weber J
    Clin Cancer Res; 2005 Feb; 11(3):1237-46. PubMed ID: 15709194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
    Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
    Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
    Kalikaki A; Kanaki M; Vassalou H; Souglakos J; Voutsina A; Georgoulias V; Mavroudis D
    Clin Lung Cancer; 2009 Mar; 10(2):118-23. PubMed ID: 19362955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients.
    Suk R; Gurubhagavatula S; Park S; Zhou W; Su L; Lynch TJ; Wain JC; Neuberg D; Liu G; Christiani DC
    Clin Cancer Res; 2005 Feb; 11(4):1534-8. PubMed ID: 15746057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients.
    Chen S; Huo X; Lin Y; Ban H; Lin Y; Li W; Zhang B; Au WW; Xu X
    Int J Hyg Environ Health; 2010 Mar; 213(2):140-5. PubMed ID: 20189873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific combinations of DNA repair gene variants and increased risk for non-small cell lung cancer.
    Popanda O; Schattenberg T; Phong CT; Butkiewicz D; Risch A; Edler L; Kayser K; Dienemann H; Schulz V; Drings P; Bartsch H; Schmezer P
    Carcinogenesis; 2004 Dec; 25(12):2433-41. PubMed ID: 15333465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
    Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
    Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A; Sørensen JB
    Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis.
    Yu D; Zhang X; Liu J; Yuan P; Tan W; Guo Y; Sun T; Zhao D; Yang M; Liu J; Xu B; Lin D
    Clin Cancer Res; 2008 May; 14(9):2878-86. PubMed ID: 18451256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer.
    Park DJ; Stoehlmacher J; Zhang W; Tsao-Wei DD; Groshen S; Lenz HJ
    Cancer Res; 2001 Dec; 61(24):8654-8. PubMed ID: 11751380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.